$3.96
-0.35-8.12%
Last update: Nov 4, 4:00 PM
Kyntra Bio Inc (KYNB) Stock Price, Quote, News & History
KYNBNASDAQ
Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.
You can purchase shares of Kyntra Bio (NASDAQ:KYNB) through any online brokerage.
Other companies in Kyntra Bio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Kyntra Bio has a consensus price target of $36.80.
The stock price for Kyntra Bio (NASDAQ: KYNB) is $4.85 last updated October 30, 2026 at 4:05 PM EDT.
There are no upcoming dividends for Kyntra Bio.
Kyntra Bio does not have any upcoming earnings scheduled.
There is no upcoming split for Kyntra Bio.
Kyntra Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk...
